Brain System Serves as 'Remote Control' for Fat Metabolism
What is known as the melanocortin system, the researchers say, controls fat metabolism and the way it accumulates in the body completely independently of food intake.
The finding, the researchers report, could lead to the development of new and urgently needed medications to treat the growing, worldwide obesity epidemic.
Led by Matthias Tschöp, MD, UC associate professor of psychiatry, and coauthored by scientists at the German Institute of Human Nutrition, the study appears in the Sept. 20, 2007, online edition of the Journal of Clinical Investigation.
The melanocortin system was previously identified as a control loop in the central nervous system (CNS) that receives hormonal signals from the gutlike those given off by hunger and satiety hormones such as ghrelin and leptinand responds to these sensations of hunger or fullness by causing the body to either ingest or burn calories.
Tschöp and colleagues say that beyond responding to signals of hunger or satiety, the melanocortin system also controls whether extra energy (glucose) will be converted to fat and whether it will be stored or metabolized.
Understanding how specific CNS circuits directly control fat storage and metabolism is essential in order to achieve a breakthrough in this important area of research, the authors write.
The group studied the melanocortin system at the molecular level in rodents. They found that when the system is stimulated to increase activity, fat is metabolized. When activity in the system is reducedeither pharmacologically or geneticallyfat accumulation increases.
We were able, in essence, to change traffic signals in so-called nutrient highways in the body so that calories were metabolized, and not dumped into fat cells, says Tschöp. And we did this without changing the rate of food intake.
These findings are relevant for human obesity, since mutations in the system we studied here are the most common known reason for genetically caused obesity in humans, Tschöp added.
The study authors also reported clinical data from
The Centers for Disease Control (CDC) and Prevention estimates that more than 30 percent of adults aged 20 to 74 are obese. Obesity increases chances for developing diabetes, heart disease and some cancers.
This study was funded by the European Union Framework 6, the Wellcome Trust and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.
Coauthors include Stephen Benoit, Tamara Castaneda, Susanna Hoffman, Philip Howles, David Hui, Ruben Nogueiras, Paul Pfluger, Diego Perez-Tilve, Brigitte Schrott and Stephen Woods, all from the University of Cincinnati; Hans-Georg Joost, Susanne Neschen, Annette Schürmann and Petra Wiedmer, all from the German Institute of Human Nutrition; Françoise Rohner-Jeanrenaud, Ildiko Szanto and Christelle Veyrat-Durebex, from the University of Geneva; I. Sadaf Farooqi, Julia Keogh and Stephen ORahilly, from Addenbrookes Hospital, Cambridge, United Kingdom; Andrew Butler and Gregory Sutton of the Pennington Biomedical Research Center; Donald Morgan and Kamal Rahmouni of the University of Iowa; and Craig Hammond from Eli Lilly Research.
Nogueiras and Tschöp are both also affiliated with the German Institute of Human Nutrition.
Tags
Related Stories
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.
Certain weather patterns can trigger migraines
June 8, 2026
Certain weather patterns really do trigger migraine headaches — and the incidence is more common in the Midwest. As WGN 9 in Chicago recently reported, researchers at the University of Cincinnati College of Medicine have identified two specific weather patterns associated with an increased risk of headaches.
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.